1802326-66-4
基本信息
3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺
JNJ 63533054
JNJ-63533054 >=98% (HPLC)
JNJ-63533054 (JNJ63533054
3-Chloro-N-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]benzamide
Benzamide, 3-chloro-N-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-
物理化学性质
| 沸点 | 559.7±45.0 °C(Predicted) |
| 密度 | 1.224±0.06 g/cm3(Predicted) |
| 储存条件 | room temp |
| 溶解度 | 溶于DMSO（高达35mg/ml）。 |
| 酸度系数(pKa) | 12.77±0.46(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| 旋光性 (optical activity) | [α]/D -89 to -99°, c = 1 in ethanol |
| 稳定性 | 可在-20°下的DMSO中的溶液保存长达2个月。 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319 |
| 防范说明 | P264-P270-P280-P301+P312-P302+P352-P305+P351+P338 |
3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/02/08 | HY-19838 | 3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺 JNJ-63533054 | 1802326-66-4 | 1 mg | 295元 |
| 2025/02/08 | HY-19838 | 3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺 JNJ-63533054 | 1802326-66-4 | 5mg | 650元 |
| 2025/02/08 | HY-19838 | 3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺 JNJ-63533054 | 1802326-66-4 | 10mM * 1mLin DMSO | 715元 |
常见问题列表
| Target | Value |
|
human GPR139
(Cell-free assay) | 0.024 μM(Ki) |
|
mouse GPR139
(Cell-free assay) | 0.054 μM(Ki) |
|
rat GPR13
(Cell-free assay) | 0.075 μM(Ki) |
JNJ-63533054 specifically activates human GPR139 in the calcium mobilization (EC
50
of 16 nM) and GTPγS binding (EC
50
of 17 nM) assays. JNJ-63533054 also activates the rat and mouse GPR139 receptor with similar potency (rat EC
50
of 63 nM, mouse EC
50
of 28 nM).
In a saturation study for human GPR139, a single population of high-affinity binding sites for [3H] JNJ-63533054 is observed (K
d
of 10 nM). The B
max
value is 26 pmol/mg of protein. Saturation studies for the rat GPR139 and mouse GPR139 yielded K
d
values within the same range (32 nM and 23 nM, respectively; B
max
= 8.5 pmol/mg of protein and 6.2 pmol/mg of protein, respectively).
JNJ-63533054 (3-30 mg/kg; oral administration; once; SD rats) treatment induces a dose-dependent reduction in locomotor activity in the first hour.
The pharmacokinetics of JNJ-63533054 (Compound 7c; 1 mg/kg iv; 5 mg/kg po) in rat is examined. The IV clearance is 53 mL/min/kg, the C
max
is 317 ng/mL (~1 μM), the t
1/2
is 2.5 hours, and JNJ-63533054 is able to cross the blood-brain barrier (BBB) with a brain to plasma ratio (b/p) of 1.2.
| Animal Model: | Male Sprague-Dawley rats (350-450 g) |
| Dosage: | 3 mg/kg, 10 mg/kg, and 30 mg/kg |
| Administration: | Oral administration; once |
| Result: | Induced a dose-dependent reduction in locomotor activity in the first hour. |